BUSINESS

Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe

February 21, 2019
Novartis Pharma AG has filed for arbitration against Mitsubishi Tanabe Pharma with the International Chamber of Commerce (ICC) claiming that the company is not obligated to pay certain royalties on sales of the multiple sclerosis treatment fingolimod, the Japanese company…

To read the full story

BUSINESS

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

By Philip Carrigan

Watching a master craftsman at work is a sight to behold.With confidence forged over years of practice, complicated steps appear effortless, problems are smoothly managed, and the final product is perfect, in every sense of the word. Within each of…